The latest price target for Spero Therapeutics (NASDAQ:SPRO) was reported by TD Cowen on November 18, 2024. The analyst firm set a price target for $0.00 expecting SPRO to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Spero Therapeutics (NASDAQ:SPRO) was provided by TD Cowen, and Spero Therapeutics downgraded their hold rating.

The last upgrade for Spero Therapeutics Inc happened on August 6, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Spero Therapeutics Inc.

The last downgrade for Spero Therapeutics Inc happened on November 18, 2024 when TD Cowen changed their price target from N/A to N/A for Spero Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Spero Therapeutics (SPRO) is trading at is $1.16, which is out of the analyst’s predicted range.